Navigation Links
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
Date:12/13/2012

Lilly will continue to develop additional treatment options for patients with autoimmune diseases."

The decision to stop the FLEX-M study is expected to result in a fourth-quarter charge in the range of $20 million to $35 million (pre-tax), or approximately $0.02 per share (after-tax). The company's previously issued financial guidance for 2012 remains unchanged.

About the FLEX-M Study

The FLEX-M study (study BCDM) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tabalumab in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to methotrexate therapy. This pivotal registration study includes the assessment of the effect of tabalumab on structural progression.   

About BAFF and Tabalumab 

BAFF (B cell activating factor) is a cytokine that promotes B cell survival, proliferation and activation. In the presence of excess BAFF, B cells, including autoreactive B cells, are not appropriately eliminated by the immune system and may therefore contribute to the development of RA by producing autoantibodies and proinflammatory cytokines and "helping" autoreactive T cells. BAFF exists in both membrane-bound and soluble forms.

Tabalumab is a human immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that inhibits both membrane-bound and soluble B cell activating factor (BAFF). Tabalumab is currently in Phase 3 development as a potential treatment for rheumatoid arthritis and systemic lupus erythematosus.

About Lilly's Autoimmune Pipeline

Tabalumab is one of three potential new medicines in late-stage clinical development for a variety of autoimmune conditions. The others are ixekizumab, an anti-IL-17 monoclonal antibody, for psoriasis and psoriatic arthritis, and baricitinib, a JAK1 and JAK2 inhibitor being developed in collaboration with Incyte Corporation, for RA, psoriasi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Provides Update on Next Steps for Solanezumab
2. Lilly to Expand Indianapolis Insulin Manufacturing Operations
3. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
4. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly Announces Results From Lung Cancer Study
7. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
8. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
9. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
10. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Michael DeMarco (42) erinnert sich kaum ... 2014 zugetragen hat. Seine Tochter Aly Demarco (13) wird ... - http://youtu.be/5cVoMCe0uiE „Man hat ... zu machen", erzählt Michael DeMarco . „Meine Frau ... Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, stand ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
(Date:11/21/2014)... 2014   Wellcentive , the industry leader ... organizations, announced today being named one of the ... Award .  Sponsored by Intel, the world leader ... year, recognizes companies developing leading-edge technology and unique ... Wellcentive,s Mason Beard , ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... activity reported against CTCL, PTCL and Ovarian ... -- CuraGen,Corporation , a clinical-stage biopharmaceutical company ... the clinical development,program for belinostat, a histone ... clinical activity of belinostat,against cutaneous T-cell lymphoma ...
... 12, 2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) today ... III clinical trial of ZYFLO CR(TM),(zileuton) extended-release tablets ... Asthma. ZYFLO CR was approved by the U.S. ... Critical Therapeutics,together with its co-promotion partner Dey, L.P. ...
Cached Medicine Technology:CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:11/23/2014)... To show thanks to new and old customers, ... evening dresses for weddings. Customers who need custom outfits ... a distinguished dress manufacturer, and it is among the ones ... a very long time. The CEO of this company says, ... able to buy not only a beautiful dress, but also ...
(Date:11/23/2014)... 2014 “BlackVue” was featured on NewsWatch ... which features the latest and coolest technology products available ... for NewsWatch, conducted the product review and shared with ... options in the car camera industry. , The need ... be hard to find the one that’s right per ...
(Date:11/23/2014)... 2014 Today Zane Benefits, the ... businesses, announced their new on demand webinar which ... Health Insurance. , According to Zane ... risk facing most American families. It is also ... large, when it comes to recruiting and retaining ...
(Date:11/22/2014)... 23, 2014 Recently, UWDress.com, a successful wedding ... wedding guest attire in order to prepare for the ... up to 70% off. , UWDress.com is a reliable ... very beautiful, especially the new items -- formal wedding guest ... the current market, including superstar and princess. As one of ...
(Date:11/22/2014)... 2014 Setria® Glutathione is now ... it for use “as a therapeutically active ingredient ... the Therapeutic Goods (Listing) Notice 2014 (No. 5) ... Setria® Glutathione will be exclusivity distributed in Australia ... and imports fine chemicals to Australian manufacturers. TGA ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... University of Illinois at Chicago College of Nursing has ... to improve the early growth and development of premature ... as poverty or minority status. , "Approximately half a ... United States," said Rosemary White-Traut, head of maternal-child nursing ...
... protein would let it thrive in upper airway, scientists say ... they,ve spotted a crucial step the deadly H5N1 bird flu ... , Since H5N1 first appeared in 1997, there have been ... Most of the human infections were the result of close ...
... EXCHANGE AND ... ELECTRONIC SUBMISSIONS, FOSTER ... its PC-LDM(TM) Suite that allows Pharmaceutical and,Biotechnology companies to instantly ... CDISC (Clinical Data Interchange,Standards Consortium) standard. FDA is anticipating that ...
... 50-70 million,sufferers, sleep disorders are one of the most ... Center on Sleep Disorder,Research. It should come as no ... disorders grows, so too does the market for,prescription sleep ... CNNMoney.com, the market for insomnia medications now tops $2,billion ...
... trouble, researchers note , THURSDAY, Oct. 4 (HealthDay ... Children,s Hospital Boston have found new information that ... a lung disease that affects premature newborns , ... or treat BPD, which can cause long-term breathing ...
... Smooth talking Mitt,Romney is heading back to the ... Bush,s veto of legislation that would provide health ... USA, September 25,2007] Despite recent polls showing that ... have provided health insurance to 10 million children,across ...
Cached Medicine News:Health News:$4 million nursing grant focuses on at-risk premature infants 2Health News:PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments 2Health News:Sleep Disorders: Waking Up to Reality 2Health News:Genes Give Clues to Newborn Lung Disease 2Health News:DNC: Romney an (S)CHIP Off the Bush Republican Block 2Health News:DNC: Romney an (S)CHIP Off the Bush Republican Block 3
... The STart 4 semi-automated hemostasis analyzer ... electro-mechanical clot detection (Viscosity-based Detection System). ... icteric or other optically turbid samples ... offers programmable and preprogrammed assays with ...
... The STA is a fully-automated, ... chromogenic and immunological assays in true ... method of sample management offers high ... samples without the need to interrupt ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
... The Electra 1800C is ... system that maximizes efficiency ... to the operator with ... is equipped with an ...
Medicine Products: